SynthesisJournal of vascular surgery. Venous and lymphatic disorders2021
A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019.
Synthesis in Journal of vascular surgery. Venous and lymphatic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04998799 (Current Practices on Antithrombotic Therapy in Hospitalised and Discharged Patients With COVID-19), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Current Practices on Antithrombotic Therapy in Hospitalised and Discharged Patients With COVID-19
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- A Growing mortality divide: demographic and regional disparities in thromboembolism with hypertension, U.S. 1999-2023.Journal of thrombosis and thrombolysis · 2026Article
- Risk of Venous Thromboembolism in Infectious Diseases: A Literature Review.Pathogens (Basel, Switzerland) · 2025Review
- Prevalence of venous thromboembolism and associated factors in COVID-19 patients at a provincial public hospital in southern Brazil.Jornal vascular brasileiro · 2025Article
- Simple demographic, laboratory and chest radiograph variables can identify COVID-19 patients with pulmonary thromboembolism: a retrospective multicentre United Kingdom study.The British journal of radiology · 2023Article
- Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital.Blood research · 2023Article
- Impact of Alteplase on Mortality in Critically Ill Patients with COVID-19 and Pulmonary Embolism.Viruses · 2023Article
- [Risk of thrombosis recurrence among patients with COVID-19- and surgery-associated venous thromboembolism].Revista clinica espanola · 2023Article
- Risk of thrombosis recurrence among patients with COVID-19 and surgery-associated venous thromboembolism.Revista clinica espanola · 2023Observational
- Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.Circulation · 2023Review
- COVID-19-Associated Thrombotic Complication: Is It Pulmonary Embolism or In Situ Thrombosis?Radiology research and practice · 2023Article
- Diagnosis and Treatment of Coagulopathy Caused by the New Coronavirus: A Systematic Review and Meta-Analysis Protocol.Advanced biomedical research · 2023Review
- Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19.Cells · 2022Review
- Perioperative Prevention of Venous Thromboembolism in Abdominal Surgery Patients Based on the Caprini or the Padua Risk Score-A Single Centre Prospective Observational Study.Life (Basel, Switzerland) · 2022Article
- Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome.Scientific reports · 2022Observational
- Extensive deep vein thrombosis and pulmonary embolism as a unique clinical manifestation of COVID-19 in a young healthy patient.Vascular · 2022Article
- Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study.Thrombosis journal · 2022Article
- Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.Science advances · 2022Article
- Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations.Research and practice in thrombosis and haemostasis · 2022Article
- COVID-19 Acute Respiratory Distress Syndrome: One Pathogen, Multiple Phenotypes.Critical care clinics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe have summarized the incidence, anticoagulation panels, laboratory characteristics, and mortality of venous thromboembolism (VTE) in hospitalized patients with coronavirus disease 2019 (COVID-19).
methodsAfter systematically searching PubMed, Embase, the Cochrane Library, MedRxiv, and BioRxiv, a systematic review and meta-analysis of 18 retrospective, 6 prospective observational, and 2 cross-sectional studies was performed according to the guidelines of the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement.
resultsOverall, 4382 hospitalized patients with COVID-19 were included. Men accounted for significantly more patients than did women (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.25-2.02; P < .001). The total incidence of VTE among the patients with COVID-19 was 28.3% (95% CI, 21.6%-35.4%), with an incidence of 38.0% (95% CI, 29.1%-47.4%) and 17.2% (95% CI, 11.4%-23.8%) among those with severe and general COVID-19, respectively. The total incidence of deep vein thrombosis (DVT) of the lower extremities was 18.3% (95% CI, 10.8%-27.2%). The incidence of DVT was 22.1% (95% CI, 11.0%-35.5%) and 12.8% (95% CI, 5.0%-23.3%) in those with severe and general COVID-19, respectively. The total incidence of pulmonary embolism was 17.6% (95% CI, 12.3%-23.5%), with a rate of 21.7% (95% CI, 14.8%-29.3%) in severe cases and 12.5% (95% CI, 6.1%-23.5%) in general cases. When COVID-19 severity was unclassified, the mortality for the patients with VTE was not significantly greater (25.2%; 95% CI, 12.2%-40.5%) than that for those without VTE (10.2%; 95% CI, 3.4%-19.5%; OR, 1.88; 95% CI, 0.46-7.64; P = .377). However, among the patients with severe COVID-19, those who had developed VTE had significantly greater mortality compared with those without VTE (OR, 2.02; 95% CI, 1.15-3.53; P = .014). The patients with COVID-19 and VTE had significantly higher D-dimer levels than did similar patients without VTE in multiple studies.
conclusionsThe occurrence of VTE, DVT, and pulmonary embolism has been substantial among hospitalized patients with COVID-19, especially among those with severe COVID-19. Patients with severe COVID-19 and VTE had significantly greater mortality compared with similar patients without VTE. An increased D-dimer level might be an indicator of the occurrence of VTE in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.